Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction

Cumberland Pharmaceuticals

04/08/2026 23:33

Overview
US biopharma firm's Q2 revenue from continuing operations fell after Apotex transaction reclassified branded business as discontinued operations
Adjusted loss per share for Q2 was $0.20
Company paid special $1.50 per share cash dividend post-transaction

Outlook
Company says it remains well-capitalized to advance its late-stage development pipeline
Cumberland expects to fund long-term product development and pursue additional strategic opportunities

Result Drivers
ASSET SALE IMPACT - Q2 results reflect completion of $100 mln sale of branded business to Apotex, with revenues from continuing operations declining and company shifting focus to drug development
PIPELINE INVESTMENT - Loss from continuing operations driven by ongoing investment in late-stage clinical programs and general expenses

Company press release: ID:nPn6Mv2n2a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
 
$0.20
 

Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."

Reuters Recommended Reads
Aug 4 - Lipocine Q2 net loss widens as revenue declines
Aug 4 - Palvella Therapeutics Q2 net loss widens on higher expenses
Aug 3 - Supernus, Indivior merge to strengthen neuroscience drug portfolio

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)